Your session is about to expire
← Back to Search
PREVENT (Preventing and Reducing Emergency Visits in Diabetes through Education and Telehealth) for Diabetes (PREVENT Trial)
Phase 3
Waitlist Available
Led By Barry W Rovner
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
PREVENT Trial Summary
This trial will compare the PREVENT intervention to intensive home-based diabetes education (EUC) to see if PREVENT can reduce diabetes-related emergency department visits and/or hospitalizations.
Eligible Conditions
- Diabetes
PREVENT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Incident Diabetes-related ED Visits and/or Hospitalizations
Secondary outcome measures
Actual Access to Care
Change From Baseline to 12 Months on Diabetes Self-Care Inventory Scores
Perceived Access to Health Care
Side effects data
From 2023 Phase 3 trial • 156 Patients • NCT0346686621%
Cardiac
13%
Gastrointestinal
12%
Infection
8%
Neurological (excluding stroke)
8%
Diabetes-related
8%
Pulmonary
6%
musculoskeletal
4%
renal
4%
Blood disorders
4%
shortness of breath
3%
Stroke
3%
COPD
1%
metabolic-not diabetes related
1%
psychiatric
1%
Respiratory
1%
Surgical
100%
80%
60%
40%
20%
0%
Study treatment Arm
EUC (Enhanced Usual Care)
PREVENT (Preventing and Reducing Emergency Visits in Diabetes Through Education and Telehealth)
PREVENT Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: PREVENT (Preventing and Reducing Emergency Visits in Diabetes through Education and Telehealth)Experimental Treatment1 Intervention
Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
Group II: EUC (Enhanced Usual Care)Active Control1 Intervention
In-home diabetes education with no goal setting or telehealth visits
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PREVENT
2016
Completed Phase 3
~260
Find a Location
Who is running the clinical trial?
Thomas Jefferson UniversityLead Sponsor
448 Previous Clinical Trials
147,606 Total Patients Enrolled
3 Trials studying Diabetes
600 Patients Enrolled for Diabetes
Barry W RovnerPrincipal InvestigatorThomas Jefferson University
Barry w RovnerPrincipal InvestigatorThomas Jefferson University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a significant problem with memory or thinking that affects your daily life.You have either Type 1 or Type 2 diabetes.You visited the emergency department due to an issue related to diabetes, as determined by the emergency department doctor.You identify as an African American.You have a medical or mental health condition that the emergency department doctor thinks would make it difficult for you to participate in the study.You are pregnant.
Research Study Groups:
This trial has the following groups:- Group 1: PREVENT (Preventing and Reducing Emergency Visits in Diabetes through Education and Telehealth)
- Group 2: EUC (Enhanced Usual Care)
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger